Welcome to Financial House......your place to Learn and Earn
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but www.stockmarketindian.com does not warrant or guarantee their accuracy or date.
www.stockmarketindian.com takes no responsibility for any investment decisions based on recommendations provided on website.
Financial contents like Technical charts, historical charts and quotes are taken from NSE and Yahoo sites.
Note - All quotes are delayed by 15 minutes and unless specified.

Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to www.stockmarketindian.com and any financial deal should be done on their own sole responsibility.
Please read our before using any material or advice given at www.stockmarketindian.com

FY17 could be a better year for pharma majors
As pharmaceutical majors grappled with the US Food and Drug Administration (FDA) on compliance, concerns on their growth in the world’s largest pharma market and thus, their overall growth increased. Sun, Lupin, Dr Reddy’s, Cadila and even Cipla and Aurobindo, all are facing  US  Food and Drug Administration (FDA) rage.

Due to lower sales of anti-diabetic generics, Glumetza. Not surprisingly, Lupin’s stock is down 17 per cent in the past week.

Sun’s US revenues have also seen softness due to limitations with the Halol plant and delay in ramp-up from other facilities. Additionally, though IMS data suggested Sun’s recently launched oncology generics drug, Gleevec, has gained 52.6 per cent market share in the US, analysts at Nomura in a note this month said data did not fully capture the entire market and, hence, its market share might be lower than reported by IMS.

The recent government ban on many fixed-dose combination (FDC) drugs also raised concern on business growth for certain companies. However, domestic majors (except Lupin) do not figure in the list of top 10 drugs by sales. While many companies have taken interim stay orders from courts, in the case of an unfavourable order, the impact for Lupin and Sun will be only Rs 0.2 and Rs 1.8 per share, respectively.

Given the series of negative news flow, pharma stocks have fallen sharply in the past 6-12 months and lagged broader markets in March, too. Most are trading 25-33 per cent lower from their peak levels.

While clearance of FDA-related issues is the single most important trigger for growth, analysts say companies are taking corrective measures. As clarity emerges, it could provide triggers. While they say the worst seems behind, there are positive developments, too.

Sun Pharma, for instance, will see synergy benefits accruing from its acquisition of Ranbaxy starting FY17-FY18.
Dr Reddy’s, with the acquisition of UCB’s product portfolio, has seen its India sales grow 33 per cent in February, whereas its niche US portfolio as injectables also faces limited competition.

Completion of the Gavis acquisition should drive Lupin’s US growth. Further, with companies having multiple production facilities, they are likely to seek site transfers from the FDA for new launches. Site transfers allow companies to undertake manufacture and export of approved drugs from other FDA-compliant plants.

Though currency headwinds could emerge, for now, the Bloomberg consensus estimates suggest earnings of top companies (except for Dr Reddy’s and Cadila) will grow upwards of 20 per cent in FY17 and by over 17 per cent (except Glenmark) in FY18. And, with valuations cheaper  (FY17 estimated PE ranges 16-20 for most companies), analysts advise long-term investors can accumulate selectively on dips.